AFMD vs. ELYM, ENLV, IFRX, RZLT, IMRX, ONCY, RVPH, LTRN, TPST, and EGRX
Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Eliem Therapeutics (ELYM), Enlivex Therapeutics (ENLV), InflaRx (IFRX), Rezolute (RZLT), Immuneering (IMRX), Oncolytics Biotech (ONCY), Reviva Pharmaceuticals (RVPH), Lantern Pharma (LTRN), Tempest Therapeutics (TPST), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.
Eliem Therapeutics (NASDAQ:ELYM) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Affimed has a consensus price target of $60.00, indicating a potential upside of 1,025.70%. Given Eliem Therapeutics' higher probable upside, analysts clearly believe Affimed is more favorable than Eliem Therapeutics.
Eliem Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.
Eliem Therapeutics has higher earnings, but lower revenue than Affimed. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Eliem Therapeutics has a net margin of 0.00% compared to Eliem Therapeutics' net margin of -638.68%. Affimed's return on equity of -33.55% beat Eliem Therapeutics' return on equity.
Affimed received 418 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 69.89% of users gave Affimed an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
In the previous week, Affimed had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 6 mentions for Affimed and 2 mentions for Eliem Therapeutics. Affimed's average media sentiment score of 0.43 beat Eliem Therapeutics' score of -0.25 indicating that Eliem Therapeutics is being referred to more favorably in the media.
69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Affimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Eliem Therapeutics and Affimed tied by winning 8 of the 16 factors compared between the two stocks.
Get Affimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools